Interleukin-6

Interleukin-6 -572G/C polymorphism and prostate cancer susceptibility

W. J. Huang, Wu, L. J., Min, Z. C., Xu, L. T., Guo, C. M., Chen, Z. P., Lou, X. J., Xu, B., Lv, B. D., Huang, W. J., Wu, L. J., Min, Z. C., Xu, L. T., Guo, C. M., Chen, Z. P., Lou, X. J., Xu, B., and Lv, B. D., Interleukin-6 -572G/C polymorphism and prostate cancer susceptibility, vol. 15, p. -, 2016.

Strong evidence suggests that cancer-associated inflammation promotes tumor growth and progression, and interleukin-6 (IL6) is an important modulator of inflammation. However, the roles of IL6 and mutations of its corresponding gene in prostate cancer have not been clearly documented. We retrieved data from the Oncomine database concerning IL6 expression in prostate cancer and its role in prostate-specific antigen (PSA) recurrence.

Meta-analysis of IL-6 -174G/C polymorphism and psoriasis risk

G. Nie, Xie, C. L., Cao, Y. J., Xu, M. M., Shi, X., Zou, A. L., Qi, J. H., Nie, G., Xie, C. L., Cao, Y. J., Xu, M. M., Shi, X., Zou, A. L., and Qi, J. H., Meta-analysis of IL-6 -174G/C polymorphism and psoriasis risk, vol. 15, p. -, 2016.

Previous studies examining the association between interleukin-6 (IL-6) -174G/C polymorphism and psoriasis risk have produced inconsistent results. The aim of this study was to offer a comprehensive review of the association between IL-6 -174G/C polymorphism and psoriasis risk through a meta-analysis. Literature search of PubMed and Embase databases was conducted to identify all eligible studies published before October 29, 2015. Four case-control studies involving 651 psoriasis cases and 552 controls were included in this meta-analysis.

Subscribe to Interleukin-6